Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure - PubMed
3 hours ago
- #Antibody-Drug Conjugate
- #Breast Cancer
- #Real-World Evidence
- Trastuzumab deruxtecan (T-DXd) showed significant real-world activity in HER2-positive metastatic breast cancer with an overall response rate of 71.9%.
- Prior exposure to trastuzumab emtansine (T-DM1) was associated with significantly shorter progression-free survival (12.1 months) compared to T-DM1-naive patients (26.0 months).
- The study included 218 patients from 21 centers in Türkiye, with 62.8% having prior T-DM1 treatment.
- Adjusted analysis indicated prior T-DM1 exposure independently increased progression risk (HR 1.99) and showed a trend toward shorter overall survival, though not statistically significant.